XENETIC BIOSCIENCES, INC. Increase (Decrease) in Accounts Payable
XENETIC BIOSCIENCES, INC. (XBIO) reported Increase (Decrease) in Accounts Payable of -$121.06 thousand for the 3-month period ending 2013-11-30, per its 10-Q filed 2014-01-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2014-01-10
- XENETIC BIOSCIENCES, INC. increase (decrease) in accounts payable for the quarter ending 2013-11-30 was -$121.06K, a 410.93% decline year-over-year.
- XENETIC BIOSCIENCES, INC. increase (decrease) in accounts payable for the quarter ending 2013-08-31 was $282.24K, a 367.08% increase year-over-year.
- XENETIC BIOSCIENCES, INC. increase (decrease) in accounts payable for the quarter ending 2013-05-31 was $17.15K, a 67.92% decline year-over-year.
- XENETIC BIOSCIENCES, INC. increase (decrease) in accounts payable for the quarter ending 2013-02-28 was -$99.29K, a 289.90% decline year-over-year.
- XENETIC BIOSCIENCES, INC. increase (decrease) in accounts payable for fiscal 2013 was $239.03K, a 30.41% increase from fiscal 2012.
- XENETIC BIOSCIENCES, INC. increase (decrease) in accounts payable for fiscal 2012 was $183.29K.
| Period end | Increase (Decrease) in Accounts Payable 1 month | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 19 month | Increase (Decrease) in Accounts Payable 22 month |
|---|---|---|---|---|---|---|---|
| 2013-11-30 | -$121.06K 10-Q · filed 2014-01-10 | $161.18K derived: sum of 2 quarters · filed 2014-01-10 | $178.33K derived: sum of 3 quarters · filed 2014-01-10 | $79.04K derived: sum of 4 quarters · filed 2014-01-10 | |||
| 2013-08-31 | $282.24K derived: 10-K 12 month − 10-Q 9 month · filed 2013-11-27 | $299.38K derived: sum of 2 quarters · filed 2013-11-27 | $200.09K derived: sum of 3 quarters · filed 2013-11-27 | $239.03K 10-K · filed 2013-11-27 | |||
| 2013-05-31 | $17.15K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-07-17 | -$82.14K derived: sum of 2 quarters · filed 2013-07-17 | -$43.21K 10-Q · filed 2013-07-17 | $17.22K derived: sum of 4 quarters · filed 2014-01-10 | $147.46K 10-Q · filed 2013-07-17 | ||
| 2013-02-28 | -$99.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-04-22 | -$60.36K 10-Q · filed 2013-04-22 | $70.00 derived: sum of 3 quarters · filed 2014-01-10 | $53.51K derived: sum of 4 quarters · filed 2014-01-10 | $130.31K 10-Q · filed 2013-04-22 | ||
| 2012-11-30 | $38.93K 10-Q · filed 2014-01-10 | $99.36K derived: sum of 2 quarters · filed 2014-01-10 | $152.80K derived: sum of 3 quarters · filed 2014-01-10 | $205.09K derived: sum of 4 quarters · filed 2014-01-10 | |||
| 2012-08-31 | $60.43K derived: 10-K 12 month − 10-Q 9 month · filed 2013-11-27 | $113.87K derived: sum of 2 quarters · filed 2013-11-27 | $166.16K derived: sum of 3 quarters · filed 2013-11-27 | $183.29K 10-K · filed 2013-11-27 | |||
| 2012-05-31 | $53.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-07-17 | $105.73K derived: sum of 2 quarters · filed 2013-07-17 | $122.87K 10-Q · filed 2013-07-17 | ||||
| 2012-02-29 | $52.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-04-22 | $69.42K 10-Q · filed 2013-04-22 | |||||
| 2011-11-30 | $17.14K 10-Q · filed 2013-01-22 | ||||||
| 2011-08-31 | $7.92K 10-K · filed 2012-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |